October 25, 2019 8:26am

As the week ends and October finishes before November crests, the wall of worry will be climbed

News: The Federal Trade Commission staff reviewing Roche's (RBO) plan to buy U.S.-based gene therapy Spark Therapeutics (ONCE) for $4.3 billion recommended that the deal be approved without requiring any asset sales

There is a sporadic sign of optimism that is the hallmark of share pricing appreciation.

When you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started …


My version of the morning’s numbers is written to be informative than just about changes to fundamentals; it’s what happened or will beyond the headline and what could happen to the future


Dow futures are DOWN -0.09% (-23 points), S&P futures are UP +0.03% (+1 points) and NASDAQ futures are UP +0.09% (+7 points)


Stock futures point to a little changing market indexes;

European stocks traded lower as the pan-European Stoxx 600 slid 0.3% by midday;

Asia Pacific markets traded mixed


Data docket: consumer sentiment figures out at 10:00 a.m. ET.



It’s Friday, a usual escape day after a week of sliding indexes – time to look a few of the oversold?

Traders are monitoring Brexit developments and the continuing exchanges between the U.S. and China.


The oversold have a shot at some appreciation as long as they are not too close to an earnings conference call, the overbought will come under scrutiny while gene therapy companies will be viewed a bit more favorable but, after those supposedly “rocketed” could be sold into.


Thursday night’s newsletter heading: “Low volume and percentage moves do not glamorize the sector for short-term investment.”

  • The NASDAQ closed UP +66 points (+0.81%);
  • The IBB closed up +0.10% while the XBI closed down -0.29%;
  • The close was negative with an A/D line of 13/27, 3 flats, 1 reversed merged (HSGX) and 2 acquired;
  • The range of the 13 upside was +0.08% (AXGN) to +8.28% (QURE) while the 27 downside ranged from -0.23% (SGMO) to -6.91% (KOOL);
  • 3 out of the 13 upside had higher than the 3 month average volume;
  • 3 out of the 27 downside had higher than the 3 month average volume;


  • October registered 7 positive, 1 neutral and 11 negative close, so far …
  • September, there were 1 holiday, 11 negative, 7 positive and 2 non reported sessions;


Companies in my headlights – It’s your decision; I provide an idea and context:

*** I haven’t changed …  follow the trading herd but … mindful of upcoming quarterly results  and their effect upon share pricing … BUY and get trampled in the coming sessions or SELL into strength or just HOLD and wait to resolve relieve the anxiety until value returns.



Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.